ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. On January 9, 2017, it was announced that ARIAD has entered into a definitive agreement to be acquired by Takeda and the transaction closed in mid-February 2017. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).
There are currently no events scheduled.More »